2025-523791-24-00CompletedPhase 1
A study investigating the effect of curcumin on the absorption and elimination of IMU 838, a new compound that may potentially be used in the treatment of multiple sclerosis, and the effect of IMU 838 on the absorption and elimination of rosuvastatin.
Source: EU CTIS (euclinicaltrials.eu) · Last updated 13 Apr 2026
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 28 (actual)
- First submitted
- 7 Nov 2025
- Start date
- 8 Jan 2026
- Lead sponsor
- Immunic AG
- Diseases
- Multiple sclerosis
- EU CT number
- 2025-523791-24-00
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 28
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Pharmaceutical Research Associates Group B.V. | Groningen | Netherlands | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.